Pacira BioSciences, Inc.
Nasdaq-listed company. Follow earnings, filings, products, capital and the competitive forces moving the company.
What’s moving Pacira BioSciences, Inc. now
Current reporting with the operating signal separated from the noise.
Pacira BioSciences, Inc. (PCRX) Q4 2025 Earnings Call Transcript
Investors are testing whether Pacira BioSciences, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Pacira BioSciences, Inc. Authorizes $300 Million Share Repurchase to Enhance Shareholder Value and Support 5x30 Growth Strategy
Investors are testing whether Pacira BioSciences, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Pacira BioSciences, Inc. Stock News: Shareholder Rights Law Firm Robbins LLP Encourages PCRX Stockholders with Large Losses to Contact the Firm to Learn About Their Rights in ...
Investors are testing whether Pacira BioSciences, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Pacira BioSciences, Inc. (NASDAQ:PCRX) Q3 2024 Earnings Call Transcript
Investors are testing whether Pacira BioSciences, Inc.’s operating performance supports its strategy and valuation.
Watch next: the filing, cash flow, guidance and capital-expenditure plan.Latest PCRX filings.
Investor-relevant reports are shown first, followed by the company’s other recent official submissions.
Pacira BioSciences, Inc., quarter by quarter.
Results, guidance and earnings coverage are grouped only when the source headline identifies the reporting period.
First quarter
No verified period-specific item in the current feed.
SEARCH Q1 COVERAGE →Second quarter
No verified period-specific item in the current feed.
SEARCH Q2 COVERAGE →